So­la­sia Pharma an­nounces Episil ap­proval in Ja­pan

BioSpectrum (Asia) - - Company News -

So­la­sia Pharma K.K. an­nounced that episil (SP-03) has been ap­proved for the man­age­ment of pain and re­lief of pain, sooth­ing oral le­sions in­clud­ing oral mu­cosi­tis/stom­ati­tis caused by chemo­ther­apy and/or ra­dio ther­apy by the Min­istry of Health, Labour and Wel­fare. So­la­sia will tar­get to ob­tain re­im­burse­ment of episil and there­after be com­mer­cial­ized, dis­trib­uted and pro­moted by its part­ner, Meiji Seika Pharma K.K. episil oral liq­uid is the first ap­proved prod­uct in Ja­pan for lo­cal treat­ment of pain associated with oral mu­cosi­tis (OM) for can­cer pa­tients un­der­go­ing chemo­ther­apy and ra­dio­ther­apy. In 2016, So­la­sia has ob­tained an ex­clu­sive li­cense to de­velop and com­mer­cial­ize episil in Ja­pan and China from Ca­mu­rus AB. In May 2016, So­la­sia filed for New Med­i­cal Device Ap­pli­ca­tion for episil in China. episil was de­vel­oped us­ing Ca­mu­rus’s pro­pri­etary tech­nol­ogy Flu­idCrys­tal. episil is ad­min­is­tered as a lipid-based liq­uid that spreads on the in­trao­ral mu­cosal sur­faces and trans­forms to a strongly bioad­he­sive film that me­chan­i­cally pro­tects the sen­si­tized and sore mu­cosa of the oral cav­ity.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.